Clinicopathologic correlations of soluble amyloid β-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls

Alzheimer Disease and Associated Disorders

Volumn 11, Issue 4, 1997, Pages 201-206

  Peskind, Elaine R ^a,b   Leverenz, J ^b   Farlow, M R ^c   Ito, R K ^d   Provow, S A ^f   Siegel, R S ^e   Cleveland, M ^d   Morgan, C H ^d   Pandian, M R ^d   Corbin, S ^b   Nochlin, D ^b   Schellenberg, G D ^a,b   Raskind, M A ^a,b   Wagner, S L ^e  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^f NONE

Author keywords

amyloid; Alzheimer disease; Cerebrospinal fluid; Soluble amyloid protein precursor (s PP)

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SOLUBILITY;

EID: 0031443808     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Altman DG. Practical statistics for medical research. New York: Chapman Hall, 1991.
2. Arai H, Lee VM-Y, Messinger ML, Greenberg BD, Lowery DE, Trojanowski JQ. Expression patterns of β-amyloid precursor protein (β-APP) in neural and noneural human tissues from Alzheimer's disease and control subjects. Ann Neurol 1991;30:686-93.
3. Bird TD, Lampe TH, Nemens EJ, Miner GW, Sumi SM, Schellenberg GD. Familial Alzheimer's disease in American descendants of the Volga Germans: probable genetic founder effect. Ann Neurol 1988;23:25-31.
4. Constantinidis J, Richard J, Tissot R. Pick's disease. Eur Neurol 1974;11:208-17.
5. Esch FS, Keim PS, Beattie EC, et al. Cleavage of the amyloid β-peptide during constitutive processing of its precursor. Science 1990;248: 1122-4.
6. Farlow MR, Ghetti B, Benson MD, Farrow JS, Van Nostrand WE, Wagner SL. Low cerebrospinal-fluid levels of soluble amyloid β-protein precursor in hereditary Alzheimer's disease. Lancet 1992;340:453-4.
7. Farlow MR, Ghetti B, Dlouhy S, et al. Cerebrospinal fluid levels of amyloid β-protein precursor are low in Gerstmann-Straüssler-Scheinker disease, Indiana kindred. Neurology 1994;44:1508-10.
8. Folstein MF, Folstein SF, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-98.
9. Francis PT, Webster MT, Proctor AW, et al. Soluble β-amyloid precursor protein and pyramidal neuron loss. Lancet 1993;341:431-2.
10. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90.
11. Henriksson T, Barbour RM, Braa S, et al. Analysis and quantitation of the β-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J Neurochem 1991;56:1037-42.
12. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer's disease: clinical predictors of institutionalization and death. Neurology 1987;37:980-4.
13. Hughes CP, Berg L, Danzinger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72.
14. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor. Nature 1987;325:733-6.
15. Khachaturian ZA. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097-105.
16. Masters CL, Multhaup G, Simm S, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid plaque cores and blood vessels. EMBO J 1985;4:2757-63.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadland EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
18. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): part II, standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
19. Neumann MA, Cohn R. Progressive subcortical gliosis, a rare form of presenile dementia. Brain 1967;90:405-18.
20. Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtellotte WW, Younkin SG. Soluble derivatives of the β-amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 1990;40:1028-34.
21. Prior R, Monning U, Schreiter-Gasser U, et al. Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid. Neursci Lett 1991;124:69-73.
22. Rozemuller AJM, Roos RAC, Bots GTAM, Kamphorst W, Eikelenboom P, Van Nostrand WE. Distribution of β-A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease. Am J Pathol 1993;142:1449-57.
23. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-71.
24. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL. Evidence that β-amyloid protein in Alzheimer's disease is not derived from normal processing. Science 1990;248:492-5.
25. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-64.
26. Van Nostrand WE, Wagner SL, Suzuki M, et al. Protease nexin II, a potent anti-chymotrypsin which shows identity to amyloid β-protein precursor. Nature 1989;341:546-9.
27. Van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid β-protein precursor. J Biol Chem 1990;265:9591-4.
28. Van Nostrand WE, Wagner SL, Haan J, Bakker E, Roos RAC. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis Dutch type share a decrease in cerebrospinal fluid levels of amyloid β-protein precursor. Ann Neurol 1992;32:215-8.
29. Van Nostrand WE, Wagner SL, Shankle WR, et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer's disease patients. Proc Natl Acad Sci USA 1992;89: 2551-5.